Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.

Date publication

octobre 2023

Journal

European urology oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Dr GEOFFROIS Lionnel , Dr THIERY-VUILLEMIN Antoine

Tous les auteurs :
Billon E, Dalban C, Oudard S, Chevreau C, Laguerre B, Barthélémy P, Borchiellini D, Geoffrois L, Negrier S, Joly F, Thiery-Vuillemin A, Gross-Goupil M, Rolland F, Priou F, Mahammedi H, Tantot F, Escudier B, Chabaud S, Albiges L, Gravis G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37813745

Résumé

Glandular metastases (GMs; adrenal gland, pancreas, thyroid, ovary, breast, or prostate) are rare in metastatic clear cell renal cell carcinoma (mccRCC). Previous studies have indicated that GM patients treated with antiangiogenic therapy experience significantly longer overall survival (OS).

Mots clés

Adrenal metastases, GETUG-AFU-26 NIVOREN trial, Glandular metastases, Immunotherapy, Nivolumab, Pancreatic metastases, Renal cell carcinoma

Référence

Eur Urol Oncol. 2023 10 7;: